Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Pan-Biome Pharmaceuticals says its compounds set it apart

Pan-Biome Pharmaceuticals says its compounds set it apart

Pan-Biome Pharmaceuticals Inc CEO Gordon Eberwein Chief Scientific Officer Poul Sorensen and Chief of Clinical Development Anne-Chloe Dhez joined Proactive’s Steve Darling to talk about the company and where they are at and where they began.

Eberwein tells Proactive some of the goals the company has over the next 6-12 months. Sorensen talks about the main focus of the company while Dhez explains the compounds and what they are designed to do.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK